Paper Details

  1. Home
  2. Paper Details

Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.

Author: AsatoTakayuki, GotoKoichi, KatayamaRyohei, KudouKentarou, KumagaiToru, NakagawaKazuhiko, NishioMakoto, OheYuichiro, SetoTakashi, ToyozawaRyo, YamamotoNobuyuki, YoshidaTatsuya, ZhangPingkuan

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC). Brigatinib demonstrated effectiveness in both TKI-naive and TKI-pretreated patients, showing a significant improvement in progression-free survival and objective response rate. Brigatinib is an important treatment option for patients with ALK+ NSCLC, including those previously treated with other TKIs.
Paper Details　
Original Abstract of the Article :
The phase 2, single-arm, multicenter, open-label J-ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC). One expansion cohort of J-ALTA enrolled patients previously treated with ALK tyrosine kinase inhibitors (TKIs); th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475780/

データ提供：米国国立医学図書館（NLM）

Brigatinib: A Treatment Option for ALK-Positive Lung Cancer

The field of oncology is constantly evolving, seeking new weapons to fight the battle against cancer. This study explores the efficacy and safety of brigatinib, a tyrosine kinase inhibitor (TKI), in Japanese patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). The researchers conducted a phase 2 clinical trial to evaluate brigatinib's effectiveness in this specific patient population.

Effective Treatment for ALK+ NSCLC

The study found that brigatinib demonstrated significant clinical activity in both TKI-naive and TKI-pretreated patients with ALK+ NSCLC. The objective response rate (ORR) was high, indicating that brigatinib effectively shrunk or eliminated tumors in a significant number of patients. The study also showed that brigatinib was well-tolerated, with a manageable side effect profile. It's like discovering a powerful weapon in the desert of lung cancer treatment, capable of effectively targeting the disease and providing patients with a fighting chance.

Expanding Treatment Options for ALK+ NSCLC

The study highlights brigatinib as a valuable treatment option for Japanese patients with ALK+ NSCLC, including those who have previously received other TKIs. This expands the range of treatment possibilities and offers hope for patients with this challenging diagnosis. It's like finding a hidden well in the desert, providing a vital source of hope and renewal for patients facing lung cancer.

Dr. Camel's Conclusion

This study offers valuable insights into the potential of brigatinib for treating ALK-positive non-small-cell lung cancer in Japanese patients. It's a promising development in the fight against this aggressive disease, providing new hope and treatment options for patients. We must continue to explore this promising area of research, seeking new weapons and strategies to defeat this formidable foe. With every new discovery, we inch closer to a future where lung cancer is no longer a threat to our health and well-being.

Date :
  1. Date Completed 2023-09-05
  2. Date Revised 2023-12-11
Further Info :

Pubmed ID

37434391

DOI: Digital Object Identifier

PMC10475780

Related Literature

Article Analysis
・Effects of brigatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.